Key result
EMD-57033 lowered the oxygen cost of contractility by 11.4% compared to a 64% increase with dobutamine (P=0.001), improving contractility without compromising diastolic function in failing hearts.
Why the study?
Does EMD-57033 improve systolic and diastolic function and mechanoenergetics compared to dobutamine and milrinone in a canine model of heart failure?
Does EMD-57033 improve systolic and diastolic function and mechanoenergetics compared to dobutamine and milrinone in a canine model of heart failure?
Absolute Event Rate: -11.4% vs 64%
p-value: p=0.001
In a canine model of heart failure, the calcium sensitizer EMD-57033 improved contractility and diastolic function while lowering the oxygen cost of contractility compared to dobutamine and milrinone.
No takes yet. Share an insight, caveat, or question.
May optimize energetics in failing hearts; leaves open translation to human HF therapy.
Senzaki et al. (2000) studied Heart failure (n=20). EMD-57033 vs. Dobutamine and milrinone was evaluated on Oxygen cost of contractility (p=0.001). EMD-57033 lowered the oxygen cost of contractility by 11.4% compared to a 64% increase with dobutamine (P=0.001), improving contractility without compromising diastolic function in failing hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: